Article

Safety of JAK and IL-6 inhibitors in rheumatoid arthritis: a multicentor cohort study

2023-06-30

Abstract excerpt

<h4>Objective: </h4> The ORAL surveillance showed a potentially higher incidence of malignancy and major adverse cardiovascular events (MACEs) with tofacitinib compared to tumor necrosis factor (TNF) inhibitors (TNFi), but little is known about safety comparisons in non-TNFi or other Janus kinase inhibitors (JAKi). This study aimed to compare the incidence (IR) of malignancies and major adverse cardiovascular even...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 503943a2-98dd-58c5-a9a6-6b2692ab6fb9
DOI: 10.21203/rs.3.rs-3112973/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety of JAK and IL-6 inhibitors in rheumatoid arthritis: a multicentor cohort studyDOI 10.21203/rs.3.rs-3112973/v1Read

Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registriesSemantic proximity Read

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseasesSemantic proximity Read

Concomitant Sjögren’s disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss Clinical Quality Management cohortSemantic proximity Read

JAK inhibitors ∼ overview∼Semantic proximity Read

The Oncology: Disease Modifying Anti-Rheumatic Drug Interface: A Cross-Specialty ReviewSemantic proximity Read

Synovial fibroblast niche shapes the efficacy–safety dynamics of JAK inhibition in rheumatoid arthritisSemantic proximity Read

Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodiesSemantic proximity Read

JAK signaling was involved in the pathogenesis of Polymyalgia RheumaticaSemantic proximity Read

Predicting the clinical efficacy of JAK inhibitor treatment for patients with rheumatoid arthritis based on Fas+ T cell subsetsSemantic proximity Read

Differences and Similarities in Clinical and Functional Responses Among Patients Receiving Tofacitinib Monotherapy, Tofacitinib Plus Methotrexate, and Adalimumab Plus Methotrexate: A Post-hoc Analysis of Data From Oral StrategySemantic proximity Read

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 TreatmentSemantic proximity Read

Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platformSemantic proximity Read